Neuroscience focus of AstraZeneca, Vanderbilt deal
Vanderbilt University has joined forces with AstraZeneca PLC in a research deal to identify potential treatments for psychosis and other psychiatric symptoms associated with diseases such as Alzheimer’s and schizophrenia
To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
About the Author
- This person does not yet have a bio.
Related Topics
Published In
Volume 9 - Issue 2 | February 2013
February 2013
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Discover how supercritical fluids expand chromatographic capabilities across diverse analytical challenges.
Evolving approaches to conjugation chemistry and linker–payload design are helping address persistent challenges in bioconjugate development.
Explore how emerging in vitro systems — built from primary cells, cocultures, and vascularized tissues — are improving translational research outcomes.
